Filtered By:
Source: Cardiology and Therapy
Countries: Sweden Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden
Conclusion
Compared with ST-APT alone, the use of rivaroxaban 2.5 mg BID in combination with ST-APT can be considered a cost-effective treatment option for ACS patients with elevated cardiac biomarkers without a prior history of stroke/TIA in Sweden.
Funding
Bayer Pharma AG.
Source: Cardiology and Therapy - June 23, 2015 Category: Cardiology Source Type: research
